APPA Shows Promise in Age Related Diseases

New data presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggests that AKL Therapeutics’ investigational oral osteoarthritis (OA) drug APPA may have a dual effect on senescence – a process in which cells stop dividing as a natural consequence of ageing. Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).

The study, using a human chondrocyte (cartilage-forming) cell line, was carried out at the Institute of Biomedical Research of A Coruña (INIBIC) in Spain: OARSI 2023 Poster.

AKL have issued a Full Press Release.